HC Wainwright Estimates Sight Sciences Q3 Earnings

Sight Sciences, Inc. (NASDAQ:SGHT) – Equities researchers at HC Wainwright issued their Q3 2026 EPS estimates for shares of Sight Sciences in a note issued to investors on Thursday, October 15th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Sight Sciences’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Sight Sciences’ Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.40) EPS and FY2027 earnings at ($0.24) EPS.

A number of other brokerages have also recently commented on SGHT. Citigroup increased their price target on Sight Sciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research note on Monday, October 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Sight Sciences in a research report on Friday, August 7th. Wall Street Zen upgraded Sight Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Finally, UBS Group upped their target price on Sight Sciences from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.00.

Sight Sciences Stock Performance

NASDAQ SGHT opened at $8.26 on Monday. The firm’s fifty day moving average price is $8.44 and its two-hundred day moving average price is $6.13. The stock has a market cap of $455.04 million, a PE ratio of -14.75 and a beta of 2.45. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.67 and a current ratio of 4.95. Sight Sciences has a fifty-two week low of $3.38 and a fifty-two week high of $9.71.

Sight Sciences (NASDAQ:SGHT) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.10. The business had revenue of $23.39 million during the quarter, compared to analysts’ expectations of $21.72 million. Sight Sciences had a negative net margin of 35.69% and a negative return on equity of 43.39%.

Institutional Investors Weigh In On Sight Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Conquis Financial LLC bought a new position in shares of Sight Sciences during the second quarter worth about $27,000. Diversified Trust Co acquired a new position in shares of Sight Sciences in the first quarter worth approximately $51,000. The Manufacturers Life Insurance Company acquired a new position in shares of Sight Sciences in the second quarter worth approximately $60,000. Ieq Capital LLC bought a new stake in Sight Sciences in the second quarter valued at approximately $135,000. Finally, Hsbc Holdings PLC bought a new stake in Sight Sciences in the first quarter valued at approximately $147,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Insider Buying and Selling at Sight Sciences

In related news, CTO David Badawi sold 7,797 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $9.05, for a total value of $70,562.85. Following the sale, the chief technology officer owned 1,975,075 shares of the company’s stock, valued at $17,874,428.75. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Brenton Taylor sold 2,988 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $8.85, for a total value of $26,443.80. Following the completion of the sale, the executive vice president owned 261,990 shares of the company’s stock, valued at $2,318,611.50. The trade was a 1.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 47,646 shares of company stock worth $429,157. Company insiders own 30.40% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc is a medical technology company focused on developing and commercializing treatments for ophthalmic diseases. The company designs devices intended to address underlying causes of conditions such as glaucoma and dry eye disease, with an emphasis on less invasive procedures that can be performed in clinical settings.

Its product portfolio includes the OMNI Surgical System, a device used in minimally invasive glaucoma surgery to perform canaloplasty and trabeculotomy procedures.